Site Map
Main Menu
Projects
- Another successful pharma divestment by PharmaVentures
- Commercialisation Strategy
- Dow Chemical
- European Biotech Licensing Transactions
- Life Sciences Valuation
- Market Sizing & Forecasting
- MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering
- Partner / Product / Technology Screening
- Pharma Deal Strategy, Deal Structuring
- Pharma Transactions, Deal Negotiations
- Pharmaceutical Company Growth
- PharmaVenture Client Bergen Bio Licenses R428
- PharmaVentures acts as advisor and broker to Dr Reddy’s to identify and secure product marketing opportunities for the Russian/CIS market.
- PharmaVentures acts as advisor to IntoCell on their ongoing collaboration agreement with Cellectar
- PharmaVentures acts as exclusive advisor on the sale of Medical Insight to Karos Health
- PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva’s Hlovovec Production Facility to Wood Pharma Holding
- PharmaVentures acts as exclusive advisor to Sanofi-Aventis in landmark divestment deal with Covance
- PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM
- PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH
- PharmaVentures advised Dogu Tip on its sale to Gulf Capital
- PharmaVentures advised Nanosight on its sale to Spectris plc.
- PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today
- PharmaVentures advises Douglas Pharmaceuticals on its licensing deal with Daré Bioscience
- PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain
- PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor
- PharmaVentures advises IDT Australia on the divestment of CMAX clinical trial business to the Japanese company I’rom Group Co. Ltd.
- PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics
- PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio
- PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies
- PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease
- PharmaVentures advises Novartis on the sale of its manufacturing facility in Barberà del Vallès to Siegfried Holding AG
- PharmaVentures advises SalvaRx Group plc on the acquisition of SalvaRx Ltd by Portage Biotech Inc.
- PharmaVentures advises Stericool on sale to Sweden’s Getinge Group
- PharmaVentures advises the Baylor Scott & White Research Institute on collaboration with Abzena plc and creation of Denceptor Therapeutics
- PharmaVentures advises Transgene on the sale of their biopharmaceutical manufacturing facility
- PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma
- PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)
- PharmaVentures Capital Limited advises Biosceptre International Limited, a clinical stage oncology company, on its Series A private placement by Tuspark S&T
- PharmaVentures Client QRx Pharma Announces Strategic Partnership with Actavis
- PharmaVentures Completes M&A Deal for Technology in the Stem Cell and Regenerative Medicine Sector
- PharmaVentures Divests Manufacturing Facility for Major Pharma Client
- PharmaVentures facilitates manufacturing divestment for UCB to Aesica Pharmaceuticals
- PharmaVentures helps secure investor for former MSD research site
- PharmaVentures’ Latest Deal: Douglas Pharmaceuticals acquires Vital Foods’ Phloe product line in New Zealand
- Series A Fundraising
- The Pharma Product/ Technology/ Company Valuation
- Valuation advisor to Yuhan Corporation on its licensing of Lazertinib for NSCLC to Janssen
Posts
Blog
- Are you Planning to Divest R&D or Manufacturing Facilities?
- Biotech Bounces Back
- Can 2014 be better than 2013?
- Convergence of Healthcare with ICT accelerates
- How to survive economic ‘Head Winds’!
- Is ‘closed-shop’ innovation a threat of new therapies and the fate of some pharma?
- Pfizer/AZ: The bigger issue is not M&A but how in the future we find effective medicines
- Pfizer+AZ: Will Mega-Merger Mania Return?
- Pharma is attracted to early-stage antibody deals in Oncology
- PharmaVentures are Media Partners at the World Stem Cells & Regenerative Medicine Congress 2015
- PharmaVentures’ Industry Insight: We predict that licensing and partnering activity will remain steady in 2020
- Season’s Greetings from PharmaVentures
- Season’s Greetings from PharmaVentures 2014
- So you know how to calculate and manage risk?
- The impact of AI on drug development
- The importance of Pricing and Market Access in licensing, partnering and early-stage development
- Vaccines, patents and supply
On Demand
PharmaVentures Insights
- Contract Manufacturing in the Pharmaceutical Industry: Recipharm
- Doing deals in the healthcare sector during the Covid-19 pandemic.
- How is M&A Shifting the Pharma Manufacturing Landscape?
- How Small/Mid-Size Firms are Shaping the Healthcare M&A Market
- How to achieve success in deal making
- Innovation in the Race to Develop COVID-19 Vaccines
- Key Questions When Doing a Deal with Big Pharma: A Conversation with PharmaVentures (한국어 버전)
- PharmaVentures InSights: The impact of conference cancellations on dealmaking during the Covid-19 pandemic
- Pricing and Market Access in Partnering
- Special Edition: A Combined Fundraising & Partnering Strategy – a Better Way to Secure Success?
- The Divestment Challenge Interview
- Video Interview: NetScientific, Fighting chronic diseases on three fronts.
- What is driving consolidation in the pharmaceutical contract services industry?
- Why you should make South Korea a deal making target
PharmaVentures Podcasts
- 4 Common Mistakes in Partnering
- Current Challenges for CROs and CDMOs in Drug Development and Supply
- Financial and Technical Aspects Driving Today’s Life Sciences Deal Making
- Medical Device and In Vitro Diagnostic Regulations are changing. How will you be affected?
- The Future of Diagnostics and the Impact on Deals
- The Importance of Pricing and Market Access in Licensing, Partnering and Early-Stage Development
- The Korean Partnering Opportunity for Western Biopharmaceutical Companies
- Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about his experience from over 30 years of dealmaking.
- Commercial Due Diligence and the Deal Making Process
- How is AI changing drug discovery today and where will it go from here?
- How to Acquire Companies or Assets Successfully
- How Your Pricing and Reimbursement Strategy Affects Your Deal Making Success
- Pharma/Biotech M&A: Insights and Trends with Soren Demin
- Review of 2022: M&A, Licensing and Fundraising
- Robust Valuations of Life Science Companies, Assets and Licensing Deals
- The Involvement of Law and Tax in Deal Making
- The Role of CDMOs in a Fast Evolving Manufacturing Landscape
Press Releases
- PharmaVentures acts as exclusive M&A advisor on the successful sale of a European pharmaceutical services operation to a US Corporation
- PharmaVentures establishes an office in Seoul to enhance access for South Korean biotechs
- A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge
- Anne Vindenes Allen Joins PharmaVentures Ltd to Head Publishing Operations
- Another successful divestment by PharmaVentures
- As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals® Resource Expands its Deal Coverage
- Biopharma Companies Gain Financially Through Unique Targeted Access to the Financial Community
- Charles Macfarlane joins Board of PharmaVentures
- Client News Update: Novartis enters exclusive talks on the potential sale of its UK Horsham site to the University of Brighton
- Deal-making declines by 18% in a year as pharmaceutical companies tighten their belt
- Determining Valuations in Challenging Times
- Essential Training an Ingredient to Success
- Good deal for Merck and Schering-Plough?
- Major New Report Highlights Growing Importance of IP Strategies and Competition Law in the Pharmaceuticals Industry
- Matrix Corporate Capital and PharmaVentures announce the signing of a Memorandum of Understanding (MOU)
- MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering
- Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
- New Industry Dynamics to Help Secure the Right Deal
- New Premium Content Service – Senior Executives at Pfizer, Johnson & Johnson, GlaxoSmithKline, and Other Big Pharma use New Media to Bring Fresh Exchange
- Novartis appoints PharmaVentures as advisors on the future of its UK Horsham site
- Pfizer – Wyeth: Good Deal – Bad Deal?
- Pfizer – Wyeth: Good Deal or Bad Deal?
- Pfizer Overtakes GSK but Trails Roche in PharmaDeals’ Corp-METRx Analysis of Deal Activity
- Pfizer, Sanofi and Genentech feature prominently in the Oncology edition of PharmaDeals’ new publication series; Essential Deal Trends
- PharmaDeals Research Reveals Early Signs of Recovery in Pharma Industry Deal Making
- PharmaTelevision Celebrates its One Year Anniversary
- PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
- PharmaTelevision Partners with Reuters Insider to Deliver BioPharma Insight to the Global Financial Community
- PharmaTelevision turns the media spotlight upon BIO-Europe
- PharmaVenture Client Bergen Bio Licenses R428
- PharmaVentures acted as advisor for sale of Dowpharma Small Molecules business to Dr Reddy’s Laboratories
- PharmaVentures acted as advisor for sale of PhotoBioChem, N.V. patent assets to SpectraCure, AB
- PharmaVentures acts as advisor and broker to Dr Reddy’s to identify and secure product marketing opportunities for the Russian/CIS market.
- PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar
- PharmaVentures Acts As Advisor to Plethora Solutions in deal with Recordati
- PharmaVentures acts as exclusive advisor on the sale of Medical Insight to Karos Health
- PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva’s Hlovovec Production Facility to Wood Pharma Holding
- PharmaVentures acts as exclusive advisor to sanofi-aventis in landmark divestment deal with Covance
- PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM
- PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH
- PharmaVentures acts as the exclusive M&A advisor on the successful sale of Phasefocus to Bruker
- PharmaVentures advised Dogu Tip on its sale to Gulf Capital
- PharmaVentures advised Nanosight on its sale to Spectris plc.
- PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today
- PharmaVentures advises Douglas Pharmaceuticals on its licensing deal with Daré Bioscience
- PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain
- PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor
- PharmaVentures advises IDT Australia on the divestment of CMAX clinical trial business to the Japanese company I’rom Group Co. Ltd.
- PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics
- PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio
- PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies
- PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease
- PharmaVentures advises Novartis on the sale of its manufacturing facility in Barberà del Vallès to Siegfried Holding AG
- PharmaVentures advises SalvaRx Group plc on the acquisition of SalvaRx Ltd by Portage Biotech Inc.
- PharmaVentures advises Stericool on sale to Sweden’s Getinge Group
- PharmaVentures advises the Baylor Scott & White Research Institute on collaboration with Abzena plc and creation of Denceptor Therapeutics
- PharmaVentures advises Transgene on the sale of their biopharmaceutical manufacturing facility
- PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma.
- PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)
- PharmaVentures and Growthink Research Join Forces to Deliver Bioscience Industry Information Solutions
- PharmaVentures and Shinhan Investment Corp sign Memorandum of Understanding to strengthen global collaboration for the Korean biopharma industry
- PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
- PharmaVentures becomes latest Partner of One Nucleus
- PharmaVentures Capital Ltd advises Biosceptre International Ltd, a clinical stage oncology company, on its Series A private placement by Tuspark S&T
- PharmaVentures Client QRx Pharma Announces Strategic Partnership with Actavis
- PharmaVentures Client Vital Foods Announces Partnership with Nestle Health Science
- PharmaVentures Completes M&A Deal for Technology in the Stem Cell and Regenerative Medicine Sector
- PharmaVentures Corporate Advisory appoints Ping Shek as Senior Director in Transactions
- PharmaVentures Divesting More Facilities for Major Pharma Companies
- PharmaVentures Divests Manufacturing Facility for Major Pharma Client
- PharmaVentures engaged by Astex Pharmaceuticals to Assist in the divestment of US facility
- PharmaVentures engaged by Avexa to Assist in the Out-licensing of Apricitabine
- PharmaVentures engaged in valuation of assets for newly AIM listed Tiziana Life Sciences.
- PharmaVentures expands corporate advisory services through new UK Financial Conduct Authority (FCA) regulated firm
- PharmaVentures expands reach to Latin America
- PharmaVentures expands their Pricing and Market Access team with the appointment of new Director, Angela Acosta
- PharmaVentures facilitates manufacturing divestment for UCB to Aesica Pharmaceuticals
- PharmaVentures further strengthens its Business Development team
- PharmaVentures gears up to shape pharmaceutical deals in Asia Pacific
- PharmaVentures Helps Deal-Making Through Beta Launch Of Its PharmaDeals® v2 Database
- PharmaVentures helps secure investor for former MSD research site
- PharmaVentures increases its Asia-Pacific presence
- PharmaVentures increases life science presence in the USA
- PharmaVentures Launches Bespoke Analysis Service
- PharmaVentures moves HQ to London to support its continued growth strategy
- PharmaVentures strengthens its expertise in early stage deal making
- PharmaVentures Strengthens Its First-Class Strategy Consulting & Dealmaking Capabilities
- PharmaVentures Strengthens M&A Team
- PharmaVentures supports GeneCode’s successful record-breaking submission to European Innovation Council Accelerator
- PharmaVentures Welcomes New Vice President in North America
- PharmaVentures’ Latest Deal: Douglas Pharmaceuticals acquires Vital Foods’ Phloe product line in New Zealand
- PharmaVentures’ new Vice President recruited to lead Pricing and Market Access practice
- PharmaVentures’ client Sanofi wins Scrip ‘Outsourcing Deal of the Year Award’
- Protecting Cash Flow Through Licensing Terms is Critical for Biotech Success
- PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund
- PTV Launches Broad Range of Services for the Global Biopharmaceutical Industry
- Roche:Genentech Integration Latest: Exclusive Interview on PharmaTelevision
- Soren Demin joins PharmaVentures as Head of M&A
- Stephen Waterman joins PharmaVentures
Termsheet
- Issue 01
- Issue 02
- Issue 03
- Issue 04
- Issue 05
- Issue 06
- Issue 07
- Issue 08
- Issue 09
- Issue 10
- Issue 11
- Issue 12
- Issue 12 Extra
- Issue 13
- Issue 14
- Issue 15
- Issue 16
- Issue 17
- Issue 18
- Issue 19
- Issue 20
- Issue 21
- Issue 22
- Issue 23
- Issue 24
- Issue 25
- Issue 26
- Issue 27
- Issue 28
- Issue 29
- Issue 30
- Issue 31
- Issue 32
- Issue 33
- Issue 34
- Issue 35
- Issue 36
- Issue 37
- Issue 38
Webinars On Demand
- Watch: CPhI Worldwide Webinar Introduction
- Watch: How is M&A Shifting the Pharma Manufacturing Landscape?
- Watch: How Small/Mid-Size Firms are Shaping the Healthcare M&A Market
- Watch: Pricing and Market Access in Partnering
- Watch: The Global Licensing Series at SEOUL BIOHUB 2020
- Watch: The Valuation Series at SEOUL BIOHUB 2021
- Watch: What is driving consolidation in the pharmaceutical contract services industry?
White Papers
- An Accommodating Environment. Ophthalmology Device Transaction Activity 2010 to 2015
- Anti-Microbial Resistance and the search for New Antibiotics
- Antibiotic Resistance, A Global Issue
- Are Diagnostics Poised to Lead Healthcare Or Is This Another False Positive?
- Are you Planning to Divest R&D or Manufacturing Facilities?
- Big Pharma Deal Making – The Beginning of a New Dawn?
- Bugs as Drugs, Microbiome Dealmaking Poised to Take Off
- China Healthcare 2.0 – Age of Consolidation, Innovation and Capital Deployment
- Co-promotion Deals – Panacea or Poison Pill?
- Competitive Deal Activity Profiling (CDAP©)
- Dancing with the Dragon Cross-border Transactions between China and the World
- Data Room Structure Guideline
- Deal Making in the Year of Covid-19
- Deal-making Metrics – Quantitative Trends in Partnering Transactions
- Diagnostics
- Dx Deal Review 2023
- Dx Deal Review Q1 2024
- Dx Deal Review Q2 2023
- Dx Deal Review Q2 2024
- Dx Deal Review Q3 2023
- Dx Deal Review Q3 2024
- EU medical device and diagnostic regulatory overhaul: Key changes and their impact
- European Rare Disease M&A Activity in 2024
- Finding and Executing Pharma Licensing Opportunities
- How South Korea is an exciting prospect for the world’s life sciences industry
- Immuno-Oncology Drives Better Outcomes In NSCLC, But Is This Now An Overcrowded Space?
- Immuno-Oncology, Revolution or Evolution?
- Industry Insight: Why Size and Timing matter
- Infection Control, Secular Growth Drivers Power Investment and M&A
- Insight into Biosimilars: Market Landscape and Key Success Factors
- Is Nationalism Transforming the Pharma Manufacturing Map?
- Key Drivers of Change in the Global Pharmaceutical Manufacturing Industry
- M&A in COVID-19 environment and beyond Keep your perspective
- Non-Small Cell Lung Cancer (NSCLC)
- Opportunities in Emerging Markets
- Options: Is the Bio/Pharma Industry Becoming More Risk Averse?
- Pharma is attracted to antibody deals in Oncology
- Pharma Services Overview
- Pharmaceutical Royalties in Licensing Deals: No Place for the 25% Rule of Thumb
- Private Equity’s Path in European Specialty Pharma M&A: Mastering 2024’s Challenges and Seizing New Opportunities
- Reducing Pain for Patients and Dealmakers
- Stars in Our Eyes – Ophthalmology Drugs Report
- Synergy or Vanity: the Appetite for Pharma Mega-Mergers
- The evolving therapeutic landscape in haematologic malignancies
- The PharmaVentures Guide: Getting your voice heard by big pharma
- The Rise of Gene Therapies in Neurological Diseases
- The Strategic Importance of Biomarkers to the Pharmaceutical Industry
- The Upsurgence of Nanotechnology
- Trends and Outlook of Licensing and M&A in the South Korean Pharmaceutical and Biotech Sector
- Trends in the CMO Landscape
- Trends in the World Small Molecule API Manufacturing M&A Market
- Understanding Headline Deal Values A PharmaVentures Guide to the Interpretation of Deal Terms and Terminology
- Valuation Series: How to Interpret and Negotiate Deal Terms for a Life Science Licensing Agreement
- Value Creation in the CDMO Market